Evidence map›Paper›PMID 26097548›Full record

ArticleInternational journal of clinical and experimental pathology2015

Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.

Ayşe Bahar Ceyran, Serkan Şenol, Bengü Çobanoğlu Şimşek, Julide Sağıroğlu, Abdullah Aydın

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2018
    Article
  5. Article
  6. Article
  7. Review
  8. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis.International journal of clinical and experimental pathology · 2017
    Article
  9. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ayşe Bahar CeyranDepartment of Pathology, Istanbul Medeniyet University Göztepe Research and Training Hospital Turkey.
Serkan ŞenolDepartment of Pathology, Istanbul Medeniyet University Göztepe Research and Training Hospital Turkey.
Bengü Çobanoğlu ŞimşekDepartment of Pathology, Istanbul Medeniyet University Göztepe Research and Training Hospital Turkey.
Julide SağıroğluDepartment of General Surgery, Istanbul Medeniyet University Göztepe Research and Training Hospital Turkey.
Abdullah AydınDepartment of Pathology, Istanbul Medeniyet University Göztepe Research and Training Hospital Turkey.
Istanbul Medeniyet University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe pathological diagnosis of papillary thyroid carcinoma (PTC) is generally easy on routine sections stained with hematoxylin and eosin (H&E). However, the differentiation of the follicular variant of PTC (FVPTC) from other suspected follicular-patterned lesions of the thyroid is highly difficult. Among these, the lesions for which FVPTC cannot be excluded are classified as well-differentiated tumors of uncertain malignant potential (WDT-UMP). The most common immunohistochemical (IHC) markers used in the differential diagnosis include HBME-1, galectin-3, and CK19. However, none of these markers provide a 100% differential diagnosis.

objectiveThe present study compared the diagnostic value of CD56 and E-cadherin for the differentiation of FVPTC from the other benign follicular-patterned lesions, with HBME-1, galectin-3, and CK19. Using these markers, the controversial cases within the WDT-UMP group were reclassified. Additionally, the relationship between the reductions in E-cadherin expression with poor prognostic factors was investigated. MATERIALS AND

methodsThe IHC expressions of CD56, E-cadherin, HBME-1, galectin-3, and CK19 were evaluated in 181 thyroid lesions, including 101 PTCs (45 classical variant PTCs and 56 FVPTCs), 20 WDT-UMPs, 20 follicular adenomas (FAs), 20 hyperplastic nodules (HN), and 20 hyperplastic foci of lymphocytic thyroiditis. The results were statistically compared via SPSS.

resultsThe expressions of all of the markers were statistically significantly different in PTC and follicular-patterned lesions (P<0.05). It was found that the only marker with both sensitivity and specificity above 90% was CD56 negativity (sensitivity 91.1%, specificity 91.7%). The most sensitive and also the most specific double panel was CD56 negativity and galectin-3 positivity (sensitivity 96%, specificity 85%), and the most sensitive and specific triple panel was CD56 negativity, HBME-1 positivity, and galectin-3 positivity (97% and 70%, respectively).

Indexed as

AdolescentAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCadherinsCarcinoma, PapillaryCD56 AntigenChildDiagnosis, DifferentialFemaleGalectin 3HumansKeratin-19MaleAntigens, NeoplasmBiomarkers, TumorCadherinsCD56 AntigenGalectin 3HBME-1 antigenKeratin-19NCAM1 protein, humanCD56E-cadherinfollicular-patterned lesionsgalectin-3HBME-1thyroid papillary cancer

Identifiers

PMID26097548
PMCPMC4466935
OpenAlexW2396178920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.